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University of York, York, North Yorkshire, UKA B S T R A C TBackground: The key principles regarding what assessments lead to
different types of guidance about the use of health technologies
(Only in Research, Approval with Research, Approve, or Reject)
provide an explicit and transparent framework for technology
appraisal. Objective: We aim to demonstrate how these principles
and assessments can be applied in practice through the use of a
seven-point checklist of assessment. Methods: The value of access to
a technology and the value of additional evidence are explored
through the application of the checklist to the case studies of
enhanced external counterpulsation for chronic stable angina and
clopidogrel for the management of patients with non–ST-segment
elevation acute coronary syndromes. Results: The case studies dem-
onstrate the importance of considering 1) the expected cost-
effectiveness and population net health effects; 2) the need for
evidence and whether the type of research required can be conducted
once a technology is approved for widespread use; 3) whether there
are sources of uncertainty that cannot be resolved by research butee front matter Copyright & 2015, International S
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ndence to: Claire McKenna, PhD, Centre for Healthonly over time; and 4) whether there are signiﬁcant (opportunity)
costs that once committed by approval cannot be recovered. Con-
clusions: The checklist demonstrates that cost-effectiveness is a
necessary but not sufﬁcient condition for approval. Only in Research
may be appropriate when a technology is expected to be cost-effective
due to signiﬁcant irrecoverable costs. It is only approval that can be
ruled out if a technology is not expected to be cost-effective. Lack of
cost-effectiveness is not a necessary or sufﬁcient condition for
rejection.
Keywords: cost-effectiveness, coverage with evidence development,
health technology assessment, only in research, reimbursement
decisions, research decisions.
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In an effort to stem the rising health care costs, many health
systems now require that a new technology demonstrate value
(i.e., that the expected additional health beneﬁts of the technol-
ogy justify its additional costs). In publicly funded health systems
such as the UK National Health Service (NHS), this is achieved by
comparing the additional health gained from the new technology
to the health expected to be forgone elsewhere in the system
(opportunity cost, which is often assessed through the use of a
cost-effectiveness threshold); that is, the technology is consid-
ered cost-effective if it offers positive net health beneﬁts.
Even in health systems in which there is an absence of ﬁrm
budget constraints or those that do not explicitly consider cost,
there is often a focus on the magnitude of health beneﬁts of the
technology, which are informally weighed against costs. In thiscase, the existence of opportunity cost remains but it may
manifest in terms of nonhealth expenditure. Therefore, decisions
about health care technologies should consider including an
assessment of the value of access to the technology, typically
relying on evidence about clinical effectiveness, impact of the
technology on long-term health and potential harms, costs, and
some assessment of the opportunity cost of health that is likely
to be forgone if the technology is approved for use.
These evidential requirements present a challenge to such
decisions because often decisions are made earlier, shortly after
regulatory approval, when the evidence base is least mature.
Consequently, the assessment of value is uncertain and subse-
quent decisions about the use of the technology are likely to be
uncertain. For example, approval of the technology may result
in resources being wasted if the expected positive net health
effects are not realized in practice, whereas rejecting theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
BY-NC-ND license
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Table 1 – Checklist for coverage with evidence development decisions.
Point Assessment Judgment (based on estimates of
expected net health beneﬁt)
Types of analyses required Yes No
1 Is the technology cost-effective?
 Estimate of expected cost-effectiveness at population level
2 Are there signiﬁcant irrecoverable costs?
 Estimate of capital investment costs, upfront costs of treatment, learning and
training costs, other potential irrecoverable costs
 Assessment of whether decisions are irreversible
 Assessment of whether costs are sufﬁciently signiﬁcant to inﬂuence guidance
3 Does more research seem worthwhile?
 Probability that technology is cost-effective
 Estimate of expected consequences of uncertainty
4* Is the research possible with approval?
 What type of evidence is required?
 Can the research be conducted if the technology is approved for use?
5 Will other sources of uncertainty resolve over time?
 Estimate of changes in the price of technology and comparators, new technology
entering, other evidence underway, other potential sources
6 Are the beneﬁts of research greater than the costs?
 Estimate of the likelihood that the research will be conducted, how much
uncertainty will be resolved, when the results will become available, and the
impact of other sources of uncertainty
 Estimate of the expected costs of research
7 Are the beneﬁts of approval greater than the costs?
 Comparison of the beneﬁts of approval and the opportunity costs (e.g., value of
research forgone as a consequence of early access)
* For technologies not expected to be cost-effective at point 1, point 4 becomes “Is the research possible without approval?”
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intervention if the net health effects prove to be greater than
expected. Therefore, the need for and value of additional evi-
dence is an important consideration when making decisions
about the use of technologies [1–3]. This is even more critical
when approval of a technology for widespread use might reduce
the prospects of conducting the type of research that would
provide the evidence needed [4]. In these circumstances, there is
a trade-off between the net health effects to current patients
from early access to the technology and the net health effects to
future patients from withholding approval until valuable
research has been conducted [5]. In making these trade-offs,
consideration should also be given to uncertain events in the
near or distant future, which may change the value of the
technology and the need for evidence [6].
Generating additional evidence through research also consumes
valuable resources that could be devoted to improving health
outcomes elsewhere. Importantly, implementing approval of a
new technology may commit resources that cannot subsequently
be recovered if guidance changes at a later date [7–9]. Therefore,
guidance about a technology will depend on whether the beneﬁts of
research are likely to exceed the costs of research and whether the
beneﬁts of early approval of the technology are expected to be
greater than the loss resulting from withholding approval until
valuable research is conducted or other sources of uncertainty are
resolved. Until recently, decisions in many health care systems
have been largely binary (i.e., approval or rejection of the
technology). However, new decision options that allow patients
early access to promising new technologies while limiting the
risks associated with making wrong treatment choices until
more evidence is established have emerged. Examples include
conditional coverage options such as “Only in Research” (OIR)
and “Approval with Research” (AWR) decisions: The formerrestricts the use of new technology to only those patients who
are involved in research, whereas the latter approves the
technology for widespread use on the condition that additional
evidence to support its continued or expanded use be collected.
A review of different health care systems’ policies for coverage
decisions linked to evidence development has been presented
elsewhere [10]; this review identiﬁed a lack of clear guidance on
the speciﬁc circumstances under which an OIR or AWR scheme
may be an appropriate policy option. Therefore, Claxton et al [10]
set out to establish the key principles of what assessments are
needed to inform OIR and AWR recommendations. The assess-
ments identiﬁed fall into four broad areas: 1) expected cost-
effectiveness and population net health effects; 2) the need for
evidence and whether the type of research required can be
conducted if a technology is approved for widespread use; 3)
whether there are sources of uncertainty that cannot be resolved
by research but only over time; and 4) whether there are
signiﬁcant (opportunity) costs that, once committed by approval,
cannot be recovered if guidance were to change at a later date. A
conceptual framework and algorithm has been developed that
identiﬁes the sequence of assessment and decisions leading to a
particular type of guidance (OIR, AWR, Approve, or Reject)
regarding the use of health technologies [10].
The sequence of assessment from this algorithm can be sum-
marized using a seven-point checklist (Table 1). A judgment at each
point of the checklist (based on estimates of expected net health
beneﬁts at each point) leads to a particular type of guidance (see
Appendix Table S1 in Supplemental Materials found at: 10.1016/j.
jval.2015.05.003 for the complete list of possible pathways). All seven
assessments do not necessarily need to be undertaken because
sometimes earlier decisions will lead directly to guidance.
The purpose of this article is to demonstrate how these
principles and assessments can be applied in practice to inform
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that explore situations in which OIR or AWRmight be particularly
relevant and challenging have been selected for this purpose. We
describe each checklist point of assessment and examine how
each of the assessments might be informed on the basis of the
type of evidence and analysis currently available and what
additional information and/or analyses might be required.Case Studies
The two case studies selected are 1) enhanced external counter-
pulsation for chronic stable angina (EECP), and 2) clopidogrel for
the management of patients with non–ST-segment elevation
acute coronary syndromes (CLOP). The cost-effectiveness of EECP
and clopidogrel has been examined previously as part of the
National Institute for Health Research Health Technology Assess-
ment program and the National Institute for Health and Care
Excellence (NICE) Multiple Technology Appraisal, respectively
[11–13]. The existing methods of appraisal have been taken as
the accepted starting point. A range of additional information
was sought and further analysis conducted to inform the
sequence of assessment and judgments required when complet-
ing the OIR/AWR checklist.
EECP is a noninvasive procedure used to provide symptomatic
relief from stable angina. The analysis compares EECP (adjunct to
standard therapy) with standard therapy alone. Randomized
controlled trial (RCT) evidence suggests an improvement in
health-related quality of life with EECP at 12 months. To charac-
terize the uncertainty associated with possible longer durations
of treatment effect, formal elicitation of expert clinical judgment
was undertaken. This provided an estimate of the probability,
with uncertainty, of a patient continuing to respond to treatment
with EECP in subsequent years [12].
EECP is expected to be cost-effective but with potentially
signiﬁcant irrecoverable costs. These irrecoverable costs include
both 1) capital costs of equipment and 2) large initial per-patient
treatment costs, combined with a chronic condition in which a
decision not to treat a particular patient can be changed at a
later date when the results of research become available or other
events occur. Consequently, these irrecoverable costs might
inﬂuence the type of guidance; for example, OIR rather than
Approve [9].
CLOP (used for up to 12 months) in combination with low-
dose aspirin was recommended by NICE after a multiple tech-
nology appraisal for patients with non–ST-segment-elevation
acute coronary syndrome who presented with a moderate to
high risk of ischemic events (TA80 in 2004 and updated in 2010 in
CG94) [14,15]. AWR was considered during the appraisal of CLOP.
Four alternative treatment durations of CLOP of 12, 6, 3, and 1
month were compared with standard therapy (with low-dose
aspirin). CLOP is expected to be cost-effective with no signiﬁcant
irrecoverable costs and illustrates a number of important char-
acteristics, including 1) the impact of other sources of uncertainty
(price change following patent expiry) on the value of research,
and 2) interpretation of multiple alternatives.Assessments Required
Point 1—Is the Technology Expected to Be Cost-Effective?
The sequence of assessment starts with cost-effectiveness and
expected impact on population net health effect (NHE) [16,17].
This requires information about prevalence and future incidence
of the population and a judgment about the time horizon over
which the technology will be used [6]. The scale of the populationNHE and how it accumulates over time are important for
subsequent assessments; for example, the NHE for current
patients must be compared with the beneﬁts to future patients
and the signiﬁcance of irrecoverable opportunity costs of initially
negative NHE must be determined.
There is a large prevalent population (109,800) eligible for EECP
relative to future incident cohorts (9500 per annum) in chronic
stable angina [18]. For CLOP, given the acute nature of non–ST-
segment-elevation acute coronary syndrome, only incident pop-
ulations are eligible for treatment (60,000 per annum) [13]. The
total population NHE for EECP and CLOP, assuming the technol-
ogies will be used to treat the population over 10 years, is
reported in Table 2. EECP is just expected to be cost-effective at
a threshold of £20,000 per quality-adjusted life-year (QALY)
gained. The incremental NHE is 1405 QALYs. For CLOP, there
are four treatment durations of 12, 6, 3, and 1 month as well as
current NHS treatment (aspirin alone). The results indicate that
12-month treatment is expected to be cost-effective at a thresh-
old of £20,000 per QALY, with a difference in NHE of 495 QALYs
between 12 and 6 months.
The “investment proﬁle” of how NHE accumulates over time
for EECP is illustrated in Figure 1. The initial costs of treatment
are high and far in excess of the immediate health beneﬁts in the
initial period of treatment. The negative NHE is gradually offset
by the positive NHE at the “breakeven” point of 17 years (14 years
at a patient level). Only after 24 years is the incremental NHE
reported in Table 2 achieved. A similar effect is observed in CLOP:
The breakeven points for CLOP are 11 years (5 years at patient
level) for 12-month treatment against standard NHS care, 27
years (21 years at patient level) for 12- month treatment against
6-month treatment, and 4 years (rather than 2 years) for 1
month-treatment against NHS care.
In summary, both EECP and CLOP are expected to be cost-
effective. From the complete list of 35 possible pathways that
lead to a particular type of guidance (see Appendix Table S1 in
Supplemental Materials), a “yes” at point 1 leaves 23 potential
pathways to be assessed at the next point on the checklist.
Point 2—Are There Signiﬁcant Irrecoverable Costs?
The second point on the checklist requires an assessment of
whether there are irrecoverable costs and a judgment of their
potential signiﬁcance. Irrecoverable costs are those that, once
committed, cannot be recovered if guidance is changed at a later
date. They are most commonly thought of as the capital costs of
new equipment or facilities with a long life expectancy. These
costs are usually annuitized and allocated pro rata to the number
of patients likely to be treated during the lifetime of the equip-
ment. Treating these upfront costs as if they are paid per patient
will have no effect as long as guidance remains unchanged. The
possibility that initial approval might be withdrawn before the
end of the lifetime of the equipment (e.g., research reports
become available or other sources of uncertainty resolve)
requires account to be taken of the fact that, although future
patients will no longer receive the technology, the total cost of
the equipment remains unchanged (i.e., must be allocated to the
smaller number of treated patients).
Irrecoverable (opportunity) costs are also present when the
initial negative per-patient costs of treatment are only compen-
sated by later health beneﬁts. The presence of this type of
irrecoverable opportunity cost, which offers an investment proﬁle
of initially negative NHE (Fig. 1), is very common. Its potential
signiﬁcance, however, depends on whether there is sufﬁcient
ﬂexibility in when a patient’s treatment can be initiated. For
example, if the treatment of a presenting patient can be delayed
until uncertainty is resolved, then the commitment of these
irrecoverable opportunity costs can be avoided (i.e., they are
Table 2 – Expected cost-effectiveness of EECP and CLOP for the population.
Cost-effectiveness threshold
£20,000 per QALY £30,000 per QALY
Treatment
(EECP)
Costs (£ million) QALY ICER (£/QALY) NHE QALY (£ million) Incremental NHE,
QALY (£ million)
NHE QALY (£ million) Incremental NHE,
QALY (£ million)
EECP 896 1,435,787 19,391 1,391,001 (27,820) 1405 (28) 1,405,930 (42,177) 16,334 (490)
Standard* – 1,389,596 – 1,389,596 (27,792) 1,389,596 (41,688)
Treatment
(CLOP)
Costs (£ million) QALY ICER (£/QALY) NHE QALY (£ million) Incremental NHE,
QALY (£ million)
NHE QALY (£ million) Incremental NHE,
QALY (£ million)
CLOP12† 10,395 4,194,554 18,663 3,674,813 (73,496) 495 (9.9) 3,848,060 (115,442) 2,798 (83.9)
CLOP6† 10,257 4,187,151 10,477 3,674,318 (73,486) 3,465 (69.3) 3,845,262 (115,358) 4,736 (142)
CLOP3† 10,180 4,179,874 9,396 3,670,853 (73,417) 3,324 (66.5) 3,840,526 (115,216) 4,305 (129)
CLOP1† 10,122 4,173,605 4,961 3,667,529 (73,351) 7,502 (150) 3,836,221 (115,087) 8,327 (250)
NHS‡ 10,072 4,163,629 – 3,660,027 (73,201) – 3,827,894 (114,837) –
CLOP, clopidogrel for the management of patients with non–ST-segment elevation acute coronary syndromes; EECP, enhanced external counterpulsation for chronic stable angina; ICER,
incremental cost-effectiveness ratio; NHE, net health effect; NHS, National Health Service; QALY, quality-adjusted life-year.
* Only the additional costs and effects of EECP over and above standard therapy are considered in the analysis.
† CLOP12, CLOP6, CLOP3, and CLOP1 correspond to treatment with clopidogrel as an adjunct to standard therapy for 12, 6, 3, and 1 month, respectively.
‡ Lifetime treatment with standard therapy alone (including aspirin).
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Fig. 1 – Cumulative incremental NHE of EECP for the population. The initial costs of EECP treatment are high and far in excess
of the immediate health beneﬁts. These negative NHEs are offset by the positive NHE after 17 years. The NHE is also affected
by the timing of expenditure; for example, whether expenditure is treated like a consumable cost by spreading the capital
cost of equipment over the technology time horizon of 10 years or whether it is incurred in full in the ﬁrst year of purchase.
EECP, enhanced external counterpulsation for chronic stable angina; NHE, net health effect; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 6 5 – 8 7 5 869potentially signiﬁcant). If the decision to treat cannot be delayed,
however, these type of irrecoverable costs cannot be avoided;
thus, they will have no inﬂuence on the type of guidance (i.e.,
irrecoverable costs are present but are not potentially signiﬁcant).
Whether the presence of potentially signiﬁcant irrecoverable
costs is likely to inﬂuence the type of guidance depends on
whether guidance is likely to change in the near or distant future.
This in turn depends on whether research is likely to be under-
taken and when it is likely to be reported, as well as other events
that might occur. These factors are assessed at points 5 and 6 in
the checklist. Therefore, whether the presence of irrecoverable
costs changes the type of guidance will become clear only at the
ﬁnal point 7 in the checklist. The presence and potential signiﬁ-
cance of any irrecoverable costs, however, can be assessed at
this point.
For EECP, the irrecoverable capital cost represents 19% of the
total cost. This will have no inﬂuence on the expected cost-
effectiveness if guidance does not change during the lifetime of
the equipment. Figure 1 shows the effect on population NHE
when these capital costs are incurred in full in the ﬁrst year
rather than allocated per patient over the lifetime of the equip-
ment. The cumulative incremental NHE is more negative in the
ﬁrst 10 years, but the “investment proﬁle” for EECP is no more
risky. Even in the absence of capital costs, EECP exhibits irrecov-
erable opportunity costs, with initially negative NHE per patient
treated. EECP is also for a chronic and stable condition in which
there is considerable ﬂexibility in when a particular patient might
start treatment with EECP. As a consequence, the treatment of
presenting patients could be delayed until the results of research
become available, thus avoiding the commitment of irrecoverable
opportunity costs. Therefore, the investment proﬁle for EECP has
potentially signiﬁcant irrecoverable costs that could inﬂuence the
type of guidance.
CLOP also exhibits irrecoverable opportunity costs, with ini-
tially negative NHE per patient treated. CLOP, however, is a
treatment for acute coronary syndromes in which there isinsufﬁcient ﬂexibility to delay the initiation of treatment for
presenting patients until the results of research reports become
available or other sources of uncertainty resolve. Therefore, in
contrast to EECP, the irrecoverable opportunity costs exhibited by
CLOP should not be judged to be potentially signiﬁcant because
they cannot be avoided by delaying the initiation of treatment for
particular patients. As a consequence, they do not have the
potential to inﬂuence guidance.
In summary, EECP has signiﬁcant irrecoverable costs, but
CLOP is not expected to have signiﬁcant irrecoverable costs that
would inﬂuence guidance. A “yes” at point 2 for EECP and a “no”
at point 2 for CLOP reduce the potential pathways from 23 to 17
(for EECP, assessments 13–29 in Table S1) and 6 (for CLOP,
assessments 1–6 in Table S1), respectively, to be assessed at the
next point on the checklist.Point 3—Does More Research Seem Worthwhile?
The third point on the checklist requires an assessment of the
potential beneﬁts of conducting further research. This requires
judgments about 1) how uncertain a decision to approve or reject
a technology might be based on expected cost-effectiveness, and
2) whether the scale of the likely consequences of this uncer-
tainty might justify further research. If the potential beneﬁts of
further research are unlikely to justify the costs, then a judgment
that more research does not seem worthwhile will lead directly to
guidance (Approve or Reject if the technology is or is not expected
to be cost-effective, respectively).
EECP is expected to be cost-effective, but estimates of cost and
QALYs are uncertain; thus, there is a chance that a decision to
approve EECP will be incorrect. Some assessment of the likely
consequences of approving EECP when standard care might be
better can be informed by probabilistic sensitivity analysis (PSA),
which provides the joint estimate of uncertainty over the model
inputs [17]. The distribution of consequences (i.e., the frequency
of errors in the decision to approve EECP across the PSA
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Fig. 2 – Distribution of the consequences of uncertainty for EECP. Most commonly, there are no consequences because a
decision to approve EECP is correct 42.8% of the time (i.e., frequency of error in the probabilistic sensitivity analysis
simulations). However, when EECP offers a lower NHE than standard care, the consequence of error may be relatively small,
for example, 9% are less than 5000 QALYs. However, there is a small chance of 5.7% that they are greater than 30,000 QALYs.
The average over this distribution provides the expected consequences of uncertainty of 9287 QALYs. EECP, enhanced
external counterpulsation for chronic stable angina; QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 6 5 – 8 7 5870simulations) is illustrated in Figure 2. Most commonly, there are
no consequences because EECP is the correct decision in 42.8% of
the simulations. When EECP offers a lower NHE than standard
care, the consequence of error may be relatively small; for
example, 9% are less than 5000 QALYs. There may, however, be
very large consequences, albeit only with a chance of 5.7% that
the consequences are greater than 30,000 QALYs. The average
over this distribution provides the expected consequences of
uncertainty of 9287 QALYs. These expected consequences can
be interpreted as an estimate of the population NHE that could be
gained over the technology time horizon if the uncertainty could
be resolved immediately; that is, it indicates an expected upper
bound on the beneﬁts of more research, which is the expected
value of perfect information [9,19,20].
CLOP with 12-month duration is expected to be not only cost-
effective but also uncertain. Decisions involving multiple alter-
natives require a judgment of the level of uncertainty, how this
uncertainty is distributed across the various alternatives, and
what the consequences are likely to be. In this case, there is a 52%
chance of no consequences because the 12-month duration with
CLOP is the correct decision. When it is not correct, there is a
greater chance of relatively small consequences (30% areo10,000
QALYs), which occur predominantly when the 6-month duration
offers the highest NHE. There is a small chance of larger
consequences (o5% that they are >30,000 QALYs) when standard
NHS treatment offers the highest NHE; that is, there remains
important uncertainty about the cost-effectiveness of CLOP itself,
not only its duration. The expected consequence of uncertainty is
5194 QALYs.The uncertainty described above reﬂects uncertainty within
the set of assumptions used to estimate expected costs and
QALYs. When more than one scenario (alternative view about
assumptions) may be credible, there will be uncertainty between
as well as within scenarios. The “weighting” of scenarios can be
made explicit by assigning probabilities to represent how credible
each is believed to be. For EECP, alternative scenarios might be 1)
no QALY beneﬁts beyond 12 months (scenario A); 2) beneﬁts
sustained for a lifetime (scenario B); and 3) sustained for 4 years
(scenario C). Formal elicitation of the judgment of clinical experts
about the likelihood of QALY gains in subsequent years was
undertaken [12], resulting in probabilities of 0.243, 0.353, and
0.404 for scenarios A, B, and C, respectively. Applying these
weights to the simulated output from the PSA gives an estimate
of expected consequences of uncertainty of 13,081 QALYs.
In summary, additional research is required for both EECP and
CLOP because the probability that EECP and CLOP is the correct
decision is around 50% and there are major expected consequen-
ces in terms of NHE if an incorrect decision is made. A “yes” at
point 3 for both EECP and CLOP reduces the potential pathways to
be assessed at the next point on the checklist from 17 to 14 for
EECP (i.e., assessments 13–26 in Table S1) and from 6 to 5 for CLOP
(i.e., assessments 1–5 in Table S1).Point 4—Is Research Possible with Approval?
The fourth point on the checklist requires an assessment of what
type of evidence is needed and a judgment of whether research
can be conducted while the technology is approved. The
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possibility. This depends, in part, on whether the type of
evidence that is needed requires an experimental research
design; for example, more precise estimates of relative treatment
effect are likely to require an RCT to avoid selection bias, but this
is unlikely to be possible once a technology is approved for
widespread use. Therefore, the fourth point requires judgments
about 1) how important particular types of parameters are to
estimates of cost and QALY; 2) what values these parameters
would have to take to change a decision; 3) how likely it is that
parameters might take such values; and 4) what the consequen-
ces would be if they did—that is, what might be gained in the
NHE if the uncertainty could be immediately resolved?
A summary of the direction and strength of the relationship
between model inputs (the parameters) and outputs (costs and
QALYs) can be provided by calculating elasticities (i.e., the
proportionate change in the NHE of each alternative due to a
1% change in the value of the parameter). These do not, however,
directly help the assessment of what values parameters must
take to change decisions and how likely such values might be.
PSA can be used to decompose the overall probabilities into the
contribution that each parameter (or group of parameters)
makes: the expected value of perfect parameter information
(EVPPI). For CLOP, uncertainty in the estimate of the relative
treatment effect on the risk of death contributes most to the
probability of error associated with 12 months of treatment
because this is the only parameter that (alone) might take values
that could make any of the other alternatives cost-effective.
An assessment of the likely consequences of this uncertainty
is now required. Again, the results of PSA can inform this
judgment because estimates of the expected consequences of
uncertainty associated with each parameter (or group of param-
eters) combines both uncertainty in its potential values and their
importance in terms of changing decisions. The corresponding
estimate of the consequences of uncertainty (or gains by resolv-
ing this uncertainty through additional research) for the relative
treatment effect of the 12-month duration of CLOP is 4433 QALYs.
Because more precise estimates of relative effect are likely to
require an RCT, a judgment that the type of research needed will
not be possible if CLOP is approved may be reasonable. The
potential beneﬁts, however, of resolving the uncertainty associated
with other groups of parameters (e.g., costs [547 QALYs] and natural
history parameters [369 QALYs]) might mean that other types of
cheaper, nonexperimental research could be worthwhile as well.
In situations in which more than one scenario might be
regarded as credible, there will be uncertainty between as well
as within each of the scenarios. The same analysis can be used to
identify the expected consequences of uncertainty associated
with the alternative scenarios themselves; that is, what might be
gained if evidence could immediately distinguish which scenario
was “true.” For EECP, using the “elicited weights” for each
scenario, the overall expected consequences of uncertainty
(combining the consequences within and between scenarios)
are 14,146 QALYs. In this case, the expected consequences of
uncertainty between the scenarios (13,202 QALYs) are much
greater than what might be potentially gained from resolving
the uncertainty within each scenario (1765 QALYs). Therefore,
unlike CLOP, most of what might be gained from further evidence
about EECP (in the absence of formal elicitation) would be
evidence that could help distinguish between the scenarios
rather than the parameters associated with each.
In summary, more research appears to be worthwhile for
EECP, but whether the research required to generate the evidence
needed can be conducted while the technology is approved for
widespread use is not clear. Therefore, a “yes/no” conclusion is
reached at point 4 for EECP. For CLOP, more research appears to
be worthwhile in the form of an RCT to reduce uncertainty in theestimate of relative treatment effect on the risk of death. Because
it is unlikely that the research could be conducted while CLOP is
approved for use—it may be unethical to enroll patients into the
trial if the treatment is already approved for widespread use—a
“no” conclusion is reached at point 4 for CLOP. This reduces the
potential pathways from 5 to 3 for CLOP (assessments 3–5 in
Table S1), whereas the number of potential pathways for EECP
remains unchanged for the next point of assessment on the
checklist.
Point 5—Will Other Sources of Uncertainty Resolve Over
Time?
The ﬁfth point on the checklist requires an assessment of
whether changes are likely to occur in the future that will
inﬂuence the cost-effectiveness of the alternative technologies
and the potential beneﬁts of research. This requires information
about 1) changes in the price of the technology and its compa-
rators, 2) the emergence of new technologies that might make
existing ones obsolete or change their cost-effectiveness, and 3)
other relevant research reporting.
Changes in price inﬂuence not only the expected cost-
effectiveness but also uncertainty and the potential beneﬁts of
research to future patients; for example, if the price falls signiﬁ-
cantly just before the results of research become available, the
potential beneﬁts will not be realized because approval of the
technology will be less uncertain. A change in the price of a
technology (or comparators) will affect the value of research
because a shift in the distribution of NHE from a technology
relative to its comparators will alter the distribution of incre-
mental NHE. For a technology that is expected to be cost-
effective, a price reduction will generally reduce the value of
additional research because the probability of decision error and
the consequences of error tend to fall. This will ultimately affect
ﬁnal guidance. For example, AWR might be revised to Approve if
the beneﬁts of early approval now exceed the value of additional
evidence. Information about major changes in price and the
likely extent of the change are required. The entry of a new
technology may also make existing technology obsolete; even
when it does not, it tends to change the relative cost-
effectiveness of the alternatives, thereby inﬂuencing how uncer-
tain a decision to approve the original technology will be for
future patients. Research that is already underway, commis-
sioned, or likely to be undertaken is also relevant because it
might have an impact on recruitment rates, and there is a chance
that it will change the estimate of cost-effectiveness when results
are reported.
For the case studies, a number of potential sources of
information were examined to identify clinical research under-
way at the time of appraisal, including national and international
trial registries and other databases that report NHS-funded
research [16]. Despite an assiduous search, no records relevant
to the case studies were identiﬁed. This may suggest that no
other research was ongoing, or it may indicate that currently
available sources are incomplete and/or difﬁcult to access. The
patent for CLOP was expected to expire 7 years later. Therefore,
the estimate, reported by the Ofﬁce of Fair Trading, that on
average generic prices tend to be 25% of the original drug price
was used in the subsequent analysis. A number of potential
sources of information were examined to identify the entry of
new technologies, including sources related to NICE topic selec-
tion; information about license applications; clinical research in
phase I, II, and III; and evidence of the probability that earlier
phase research leads to entry and the likely time of entry. The
information that was available indicated that one new technol-
ogy relevant to CLOP might have been expected to enter the
market.
Resolve all uncertainty 
Resolve uncertainty in relative treatment effect 
Price change at year 7
Fig. 3 – Potential value of research and time to report (CLOP).
The potential value of research declines with the time it
takes research to report, which gives an indication of the
value of improving the timeliness of research. Research will
not resolve all uncertainty, and other sources of uncertainty,
such as price change, will have an impact on the value of
research. CLOP, clopidogrel for the management of patients
with non–ST-segment elevation acute coronary syndromes.
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research) were identiﬁed for EECP. For CLOP, the patent was
expected to expire at a later point in time, and other information
indicated that a new technology relevant to CLOP might be
expected. Therefore, a “no” at point 5 is reached for EECP,
whereas a “yes/no” conclusion is reached for CLOP. This reduces
the potential pathways from 14 to 6 for EECP (assessments 17–26
in Table S1), whereas the number of potential pathways for CLOP
remains unchanged (assessments 3–5 in Table S1) for the next
point of assessment on the checklist.
Point 6—Are the Beneﬁts of Research Greater than the Costs?
The sixth point on the checklist requires a judgment of whether
the beneﬁts of research are likely to exceed the costs. This
requires an assessment of 1) the likelihood that research will beTable 3 – Population NHE over the technology time horiz
CLOP Approve OIR AWR* Reject
Expressed in QALY
T o T* (T ¼ 2) 3,680,187 3,681,480 3,682,995 3,671,660
T 4 T* (T ¼ 7) 3,680,187 3,675,487 3,680,362 3,671,660
NHE expressed in £ million
T o T* (T ¼ 2) 73,604 73,630 73,660 73,433
T 4 T* (T ¼ 7) 73,604 73,510 73,607 73,433
EECP Approve OIR AWR Reject
Expressed in QALY
T ¼ 3 1,391,001 1,397,192 1,393,578 1,389,596
T ¼ 7 1,391,001 1,393,608 1,392,030 1,389,596
Expressed in £ million
T ¼ 3 27,820 27,944 27,872 27,792
T ¼ 7 27,820 27,872 27,841 27,792
AWR, Approval with Research; CLOP, clopidogrel for the management of
EECP, enhanced external counterpulsation for chronic stable angina; NHE
year.
* Expected population NHE if AWR is a possibility.
† Difference between AWR and the next best feasible policy (OIR for T o
‡ Maximum NHE for the resolution of all uncertainty immediately.
§ Difference between the maximum NHE for the resolution of all uncertconducted, 2) when the results are likely to be available, 3) how
much uncertainty is likely to be resolved, and 4) the likely impact
of any other sources of uncertainty identiﬁed at point 5. The
decision at this point can lead directly to guidance. However, if
the beneﬁts of research exceed the costs but research is not
possible with approval, or if there are signiﬁcant irrecoverable
costs, guidance will depend on whether the beneﬁts of approval
are judged to exceed the costs (point 7 of the checklist).
Even if research is recommended in OIR or AWR, it might not
be undertaken or completed. The potential gains from research
depend on the likelihood of successful completion and the time
taken to report the results. For example, if treatment decisions
are irreversible in CLOP, it is only those patients incident after
research is reported who will realize any of the potential beneﬁts.
If treatment decisions are reversible (chronic condition)—for
example, in EECP—patients prevalent while the research is
undertaken will not beneﬁt immediately, but those who survive
can beneﬁt from the results. How long research might take to
report will depend, in part, on the design, recruitment, size of
population, and efﬁciency of data collection.
Most research will not inform all the parameters that deter-
mine the expected cost and QALYs. Therefore, the potential
beneﬁts of research will not be the total expected costs of
uncertainty but instead some part of it. The potential value of
research for CLOP over a range of times to report is illustrated in
Figure 3 for all parameters and relative treatment effects. The
potential value of research is likely to exceed the costs unless
research takes more than 8 years to report. The patent for CLOP
was due to expire 7 years after the appraisal. In this case, a
signiﬁcant fall in price in year 7 will substantially reduce the
uncertainty surrounding 12 months of treatment with CLOP. If
the new technology expected to enter the market at year 5 makes
CLOP obsolete, there is no value in the evidence generated by
research about CLOP. However, if the new technology has an NHE
similar to that of CLOP and the uncertainty surrounding its
expected cost-effectiveness is also similar, research about CLOP
has more potential value in the future because it will also helpon for different policies.
Value of
AWR†
Uncertainty
resolved at launch‡
Value of evidence
at launch§
1515 3,684,181 2701
175 3,684,181 3994
30 73,684 54
4 73,684 80
Value of
AWR
Uncertainty resolved
at launch
Value of evidence
at launch
–3614 1,400,288 3096
–1578 1,400,288 6680
–72 28,006 62
–32 28,006 134
patients with non–ST-segment elevation acute coronary syndromes;
, net health effect; OIR, Only in Research; QALY, quality-adjusted life-
T* and Approve for T 4 T* for CLOP; OIR for EECP).
ainty immediately and the next best available policy.
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Fig. 4 – An OIR or AWR boundary (EECP). A boundary for when OIR rather than AWR might be appropriate for four research
designs with different lengths of follow-up. For EECP, the type of research required is likely to report quickly for all research
designs and with sufﬁcient conﬁdence that OIR would be appropriate even though the research could be conducted while
EECP is approved. AWR, Approval with Research; EECP, enhanced external counterpulsation for chronic stable angina; OIR,
Only in Research.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 6 5 – 8 7 5 873resolve some of the uncertainty in the choice between CLOP and
the new technology for patients who become incident after
that time.
In summary, the beneﬁts of research are expected to be
greater than the costs for EECP (although this will depend, in
part, on research design) because the value of resolving the
uncertainty at points 3 and 4 is very high relative to any expected
costs of research. For CLOP, the potential value of research is
likely to exceed the costs unless the research takes more than 8
years to report and assuming that the new technology has NHE
similar to that of CLOP. Therefore, a “yes” at point 6 is reached for
both EECP and CLOP, which reduces the potential pathways from
6 to 4 for EECP (assessments 17 and 18 and 24 and 25 in Table S1)
and from 3 to 2 for CLOP (assessments 3 and 4 in Table S1) for the
next point of assessment on the checklist.
Point 7—Are the Beneﬁts of Approval Greater than the Costs?
The ﬁnal point on the checklist requires a comparison of the
beneﬁts of approval and early access to current patients and the
opportunity costs to future patients. The opportunity costs
include the potential value of any research that may be forgone
as a consequence and irrecoverable costs committed by approval.
The decision at this point always leads directly to guidance.
Research that would provide more precise estimates of the
relative treatment effect of CLOP and shorter treatment durations
is potentially valuable, but it is unlikely to be possible if 12
months of treatment is already approved for widespread use.
Therefore, AWR may not be possible, and so the beneﬁts of early
access with CLOP (Approval) must be compared with the poten-
tial value of OIR. The difference in NHE between Approve and OIR
over a range of times when research might be reported (taking
account of the expected change in price at year 7 and research
costs of £10 million) indicates that OIR will be appropriate only if
the research is reported within 3 years of appraisal (T* ¼ 3)because beyond this time the NHE forgone by withholding access
to CLOP will exceed the potential gains to future patients. There
is no guarantee, however, that the research recommended as part
of OIR guidance will be conducted. Therefore, the probability that
research will report at a particular time also needs to be
considered. If research is certain to report but will take 4 years,
or if there is only a 50% chance of reporting within 1 year, then
OIR would not be appropriate and 12-month treatment of CLOP
should be approved.
The assessments for CLOP are summarized in Table 3. The
difference in NHE between AWR (if possible) and the next best
feasible policy (OIR when To T* and Approve when T4 T*) is £30
million and £4 million, respectively. The difference in NHE if all
uncertainty was resolved prior to appraisal (at launch) and the
next best available policy (OIR when T o T* and Approve when T
4 T*) is £54 million and £80 million, respectively, and represents
the value of having access to the evidence needed at launch. This
can inform policies that might make better and more relevant
evidence available.
Unlike CLOP, EECP has signiﬁcant irrecoverable opportunity
costs. As a consequence, even if research is possible with
approval, it is not clear that AWR would be appropriate because
OIR avoids the commitment of irrecoverable costs until research
ﬁndings are available and a more informed decision can be made.
In this case, OIR offers greater expected NHE than AWR as long as
research reports before 9 years. A boundary for when OIR rather
than AWR might be appropriate is illustrated in Figure 4 for four
research designs with differing follow-up lengths.
For the same reasons as CLOP, however, the type of exper-
imental research required may not be possible. Now approval
(through Approve rather than AWR) not only commits the type of
irrecoverable costs discussed above but it also means that the
potential value of evidence to future patients must also be
forgone. The assessments for EECP are also summarized in
Table 3. The difference between OIR and Approve is greater than
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 8 6 5 – 8 7 5874that between OIR and AWR. As long as the cost of the research
exceeds the difference between OIR and Approve, OIR would be
appropriate. The NHE for AWR is negative, indicating that even if
AWR was possible it would not be appropriate. Like CLOP, having
the evidence needed before appraisal is of value to the NHS,
dependent on how long it would otherwise have taken for an OIR
recommendation to deliver the same evidence; for example, £62
million if 3 years or £134 million if 7 years. The decision at this
point always leads directly to guidance.
In summary, guidance for EECP will depend on whether
technology can be approved for widespread use while research
is conducted (i.e., yes/no at point 4 determines whether AWR is a
possibility). The analysis at this ﬁnal point, however, demon-
strates that even when research is possible with approval, OIR
appears to offer the greater expected NHE than does AWR or
Approve as long as research reports before 9 years. This is largely
because the consequences of committing signiﬁcant irrecover-
able costs through AWR or Approve are greater than the NHE
forgone by restricting access to EECP through OIR. For CLOP,
research was not considered possible with approval, and so the
beneﬁts of early access to 12 months of treatment with CLOP
(Approval) must be compared with the potential value of OIR. The
analysis at this ﬁnal point indicates that if research reports
earlier than 3 years, OIR would be appropriate; otherwise,
Approve would be more appropriate.Discussion
Decision options of OIR and AWR have emerged in many health
care systems to balance the need for early access to a technology
and the need for valuable research to be conducted. In the United
States, the term “coverage with evidence development” is often
used as a catch-all term for OIR/AWR-type schemes. The Centers
for Medicare and Medicaid Services issue both OIR- and AWR-
type coverage decisions under two distinct processes of coverage
with appropriate determination and coverage with study partic-
ipation [21]. In the United Kingdom, an OIR scheme can be
recommended by NICE when appraising technologies. Following
an OIR recommendation, however, there are no formal arrange-
ments to develop the research study required to reduce uncer-
tainties [22]. NICE does not hold a budget to commission
research, and, therefore, much of the burden falls on the
manufacturer.
Several previous attempts have been made to develop taxon-
omies for conditional coverage and risk-sharing schemes [23–27].
However, these have not speciﬁcally focused on OIR/AWR
schemes. For example, in the taxonomy developed by Carlson
et al [23], conditional coverage schemes are divided into coverage
with evidence development and conditional treatment continu-
ation schemes. Within coverage with evidence development, two
subtypes are presented: OIR and “Only with Research,” wherein
Only with Research is similar to AWR.
Claxton et al [10] set out to develop a set of principles and
criteria that may be required to reach OIR/AWR-type decisions.
The result was a sequence of assessments and judgments,
summarized as a seven-point checklist. This article has illus-
trated the use of the checklist to two case studies.
The analysis shows how the checklist might be operational-
ized, what types of analyses might feasibly be included within an
appraisal process, and how the results might be interpreted to
inform the judgments required. We also show how the different
types of guidance (Approve, AWR, OIR, or Reject) might be
reached in different ways. The order of considerations means
that all seven assessments do not necessarily need to be made
when an earlier judgment can lead directly to guidance. The
assessment of whether further research might be worthwhileand what type of evidence might be required would need to be
undertaken routinely under such a framework. If research may
be worthwhile, some indication of the type of evidence needed
would also be useful for those making an assessment of the
prospects of research and whether the type of research required
to generate it would be possible with approval. Therefore, routine
assessment up to point 4 of the checklist would seem appropriate
before others with expertise in and responsibility for research
design and commissioning consider the prospects of conducting
research.
A limitation of this analysis is a lack of consideration of the
diffusion of technologies. The potential health beneﬁts of con-
ducting further research are realized (i.e, patient outcomes
actually improve) only if the ﬁndings of the research have an
impact on clinical practice. There may be other mechanisms (e.g.,
more effective dissemination of existing evidence) or policies that
fall within the remit of other bodies to inﬂuence the implemen-
tation and diffusion of technologies rather than acquiring addi-
tional evidence [28].
These case studies have demonstrated the feasibility of
applying the checklist without requiring any substantial reanal-
ysis of the original assessments. The information required to
assess whether other sources of uncertainty will resolve over
time (point 5 on the checklist), however, requires information
that is not commonly reported during an appraisal process. It is
also recognized that some amendments might be required when
cost-effectiveness is not the prime consideration. Furthermore,
the application of the checklist alone is unlikely to be sufﬁcient
because no quantitative analysis can capture all aspects of
scientiﬁc and social value judgments. Therefore, the most rele-
vant question is whether these methods offer a practical and
useful starting point for deliberation and add to the transparency
and accountability of adoption decisions.Acknowledgments
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